Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REVAMP: Risankizumab vs Vedolizumab in Targeted Therapy-Naïve Ulcerative Colitis
NCT06880744Phase 3Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Jun 2025
- Primary completion
- Aug 2027
- Modality
- Monoclonal Antibodies
- Countries
- 31
01
Overview
A Phase 3 trial of risankizumab in ulcerative colitis (UC), sponsored by AbbVie Inc.. Started Jun 2025; status: active, not recruiting.
02
Drugs
risankizumab
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT06880744.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06880744.